（文章来源：每日经济新闻） 建发致新（301584.SZ）12月8日在投资者互动平台表示，公司目前没有组织开展脑机接口领域的专项课 题研究，没有经营脑机接口类医疗产品。 每经AI快讯，有投资者在投资者互动平台提问：请问贵公司旗下有组织开展脑机接口领域的专项课题 研究吗？公司的产品是否有应用在脑机接口领域？ ...

证券代码：301584 证券简称：建发致新 公告编号：2025-015 上海建发致新医疗科技集团股份有限公司 关于为下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 上海建发致新医疗科技集团股份有限公司（以下简称"公司"或"建发致 新"）及控股子公司提供担保总额超过公司最近一期经审计净资产100%，对资产 负债率超过70%的控股子公司预计担保金额超过公司最近一期经审计净资产50%， 前述担保均为对公司合并报表范围内子公司的担保，财务风险处于公司可控范围内， 提请投资者充分关注担保风险。 一、对外担保情况概述 根据公司经营发展战略、资金预算和资金安全等需要，自公司2024年年度股 东大会之日起，至2025年年度股东大会召开之日止，公司及控股子公司拟向各银行 等金融机构申请综合授信总额不超过人民币150亿元，以上事项已经公司2024年年度 股东大会和2025年第二次临时股东大会审议通过。 鉴于上述授信总额中部分授信额度的融资主体为公司控股子公司，为保障子公 司顺利申请授信额度，自公司2024年年度股东大会之日起，至202 ...

（文章来源：证券日报） 证券日报网讯 12月4日，建发致新在互动平台回答投资者提问时表示，截至11月30日，公司股东人数为 30237户。 ...

格隆汇12月4日丨建发致新(301584.SZ)在投资者互动平台表示，公司目前没有组织开展脑机接口领域的 专项课题研究。 ...

Core Points - The Shenzhen-Hong Kong Medical Index (983035) closed at 4494.42 points, up 0.15%, with a trading volume of 7.52 billion yuan and a turnover rate of 0.75% [1] - Among the index constituents, 32 stocks rose while 24 fell, with Medical Pulse leading the gainers at 3.65% and Health Road leading the decliners at 3.41% [1] Index Constituents Summary - The top ten constituents of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (14.56% weight, latest price 196.30 yuan, market cap 238 billion yuan, up 1.50%) [1] - Yier Eye Hospital (11.62% weight, latest price 11.40 yuan, market cap 106.31 billion yuan, down 0.26%) [1] - Lejin Medical (4.85% weight, latest price 15.87 yuan, market cap 29.26 billion yuan, up 0.13%) [1] - Aimeike (4.80% weight, latest price 146.26 yuan, market cap 44.26 billion yuan, up 0.83%) [1] - Yuyue Medical (4.66% weight, latest price 35.70 yuan, market cap 35.79 billion yuan, down 0.67%) [1] - Yingke Medical (3.64% weight, latest price 41.53 yuan, market cap 27.21 billion yuan, up 1.94%) [1] - Furuide (3.59% weight, latest price 67.08 yuan, market cap 17.78 billion yuan, up 1.36%) [1] - Meinian Health (3.58% weight, latest price 5.28 yuan, market cap 20.67 billion yuan, down 1.68%) [1] - Sinopharm (3.35% weight, latest price 18.42 yuan, market cap 57.48 billion yuan, down 0.69%) [1] - Ping An Good Doctor (2.63% weight, latest price 13.66 yuan, market cap 29.52 billion yuan, down 1.83%) [1] Capital Flow Analysis - The net outflow of main funds from the index constituents totaled 58.83 million yuan, while retail investors saw a net inflow of 78.07 million yuan [1] - Specific stock capital flows include: - Aimeike: Main fund net inflow of 46.99 million yuan, retail net outflow of 30.07 million yuan [2] - Mindray Medical: Main fund net inflow of 33.08 million yuan, retail net outflow of 17.11 million yuan [2] - Furuide: Main fund net inflow of 13.68 million yuan, retail net outflow of 19.08 million yuan [2] Recent Adjustments - The Shenzhen-Hong Kong Medical Index has undergone adjustments in the last 10 days, with one new stock added [2]

Market Overview - The pharmaceutical commercial sector increased by 1.34% compared to the previous trading day, with Huaren Health leading the gains [1] - The Shanghai Composite Index closed at 3864.18, down 0.15%, while the Shenzhen Component Index closed at 12907.83, up 1.02% [1] Stock Performance - Huaren Health (301408) saw a closing price of 17.40, with a significant increase of 20.00% and a trading volume of 345,500 shares, amounting to a transaction value of 570 million [1] - Other notable performers included: - Haiwang Biological (000078) with a closing price of 2.81, up 10.20% [1] - Renmin Tongtai (600829) at 13.18, up 10.02% [1] - Ruikang Pharmaceutical (002589) at 3.19, up 10.00% [1] - Yingte Group (000411) at 12.36, up 9.96% [1] Capital Flow - The pharmaceutical commercial sector experienced a net inflow of 665 million from main funds, while retail funds saw a net outflow of 366 million [2] - The main funds' net inflow for Huaren Health was 1.43 billion, representing 25.12% of the total, while retail funds had a net outflow of 596.87 million [3] - Other companies with significant main fund inflows included: - Ruikang Pharmaceutical with a net inflow of 118 million [3] - Renmin Tongtai with a net inflow of 115 million [3] - Haiwang Biological with a net inflow of 106 million [3]

Core Viewpoint - The company Jianfa Zhixin has shown a slight decline in stock price, with a trading volume of 327 million yuan and a net financing inflow of 1.69 million yuan on November 25, indicating ongoing investor interest despite the minor price drop [1]. Financing Summary - On November 25, Jianfa Zhixin had a financing buy-in amount of 27.29 million yuan, with a total financing balance of 96.47 million yuan, representing 5.81% of its market capitalization [1]. - The company reported no short-selling activity on the same day, with a short-selling balance of 0 yuan [1]. Business Performance - As of September 30, Jianfa Zhixin had 38,000 shareholders, an increase of 151.60% from the previous period, while the average number of circulating shares per shareholder decreased by 60.25% [2]. - For the period from January to September 2025, the company achieved a revenue of 14.861 billion yuan, reflecting a year-on-year growth of 10.18%, and a net profit attributable to shareholders of 230 million yuan, which is a 45.01% increase year-on-year [2]. Company Overview - Jianfa Zhixin Medical Technology Group Co., Ltd. was established on August 30, 2010, and is located in Yangpu District, Shanghai. The company specializes in the direct sales and distribution of medical devices and provides centralized operation services for medical consumables to hospitals [1]. - The main revenue sources for the company include vascular intervention (55.61%), surgical instruments (21.46%), in vitro diagnostic reagents (13.05%), medical equipment (6.24%), and other medical devices (2.79%) [1].

Market Overview - As of November 21, the Shanghai Composite Index closed at 3834.89 points, down 96.16 points, a decline of 2.45% [1] - The Shenzhen Component Index closed at 12538.07 points, down 442.75 points, a decline of 3.41% [1] - The ChiNext Index closed at 2920.08 points, down 122.26 points, a decline of 4.02% [1] Trading Activity - A total of 91 A-shares had a turnover rate exceeding 20% on this day [1] - Notable stocks with high turnover rates included: - Dapeng Industrial (920091) with a turnover rate of 98.28% and a price increase of 1211.11% [1] - Jianglong Shipbuilding (300589) with a turnover rate of 55.14% and a price increase of 14.50% [1] - C Nanshan Data (301638) with a turnover rate of 52.72% and a price increase of 0.91% [1] Notable Stocks - Other significant stocks with high turnover rates included: - C Hengkun (688727) with a turnover rate of 46.22% and a price decrease of 11.47% [1] - Inspur Software (600756) with a turnover rate of 46.20% and a price increase of 6.76% [1] - ST Dongtong (300379) with a turnover rate of 44.50% and a price increase of 4.15% [1] - Additional stocks with notable performance included: - Shennong Agriculture (300189) with a turnover rate of 42.82% and a price increase of 3.67% [1] - Beifang Changlong (301357) with a turnover rate of 42.52% and a price increase of 0.68% [1]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.51% on November 20, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers included: - HeFu China (603122) with a closing price of 26.18, up 10.00% [1] - KaiKai Industry (600272) at 14.58, up 4.14% [1] - Zhejiang Zhenyuan (000705) at 9.91, up 1.64% [1] - Major decliners included: - Renmin Tongtai (600829) at 14.36, down 9.97% [2] - Jianfa Zhixin (301584) at 32.34, down 4.88% [2] - Shuyupingmin (301017) at 13.40, down 3.11% [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 260 million yuan from institutional investors, while retail investors had a net inflow of 264 million yuan [2] - The overall capital flow indicates a shift in investor sentiment, with retail investors showing more interest in the sector [2] Individual Stock Capital Flow - Shanghai Pharmaceuticals (601607) had a net inflow of 36.98 million yuan from institutional investors, but a net outflow from retail investors [3] - KaiKai Industry (600272) also saw a net inflow from institutional investors of 27.76 million yuan, with retail investors showing a net outflow [3] - Other stocks like Zhejiang Zhenyuan (000705) and Dajia Weikang (301126) experienced mixed capital flows, indicating varied investor interest [3]

Summary of Key Points Core Viewpoint - Shanghai Jianda Zhixin Medical Technology Group Co., Ltd. is providing guarantees for its subsidiaries, with a total guarantee amount expected to reach up to 7 billion RMB, reflecting the company's strategic financial management and support for its subsidiaries' operations [3][4]. Group 1: Guarantee Overview - The company plans to apply for a total credit limit of no more than 15 billion RMB from banks and financial institutions from the 2024 annual general meeting until the 2025 annual general meeting [3]. - The expected total guarantee amount for subsidiaries is capped at 7 billion RMB, with 6.5 billion RMB allocated for subsidiaries with an asset-liability ratio exceeding 70% and 500 million RMB for those below this threshold [3][4]. Group 2: Recent Guarantee Developments - Recently, the company provided joint liability guarantees totaling 780 million RMB for several subsidiaries, including Shanghai Jianda Luyi Technology Co., Ltd. and Beijing Kangle Zhixin Supply Chain Management Co., Ltd. [6][7]. - The guarantee amount for Fujian Del Medical Industry Co., Ltd. is 1.75 billion RMB, which includes a portion allocated for supply chain finance activities [7]. Group 3: Financial Metrics and Risk Management - After the current guarantees, the total utilized guarantee amount is 5.825 billion RMB, representing 393.27% of the company's latest audited net assets attributable to shareholders [15]. - The actual guarantee balance stands at 2.447 billion RMB, which is 165.23% of the company's latest audited net assets [15][16]. - The company has not provided guarantees to entities outside the consolidated financial statements and has no overdue guarantees or litigation-related guarantees [16].